Keywords: pharmathene, gets, 6m, continue, protexia, development, biodefense

PharmAthene gets $1.6M to continue Protexia development

Article | 20 October 2008

PharmAthene, a US biodefense company developing medical countermeasures against biological and chemical threats, says that the Consolidated Security, Disaster Assistance, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Go to drug listing